Latest Advances in Lung Cancer Research

Leading lung cancer specialists discuss revolutionary advances in treating EGFR-mutated non-small cell lung cancer, highlighting how new combination therapies like amivantamab plus chemotherapy are doubling progression-free survival and offering hope for patients with challenging complications like leptomeningeal metastases, while emphasizing practical strategies for managing treatment side effects in community practice.

New drug shrinks HER2-mutant lung cancer tumors in 73% of patients, offering hope for improved treatment options.

Osimertinib after surgery significantly improves survival in early-stage EGFR-mutated NSCLC, reducing cancer recurrence and offering a new standard of care.

The FDA has approved amivantamab for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

This article reviews strategies for managing treatment resistance in advanced EGFR-mutated lung cancer, focusing on personalization, parsimony, and partnership.

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Adagrasib shows promise in treating KRAS G12C-mutant NSCLC, with lasting responses and potential as a much-needed targeted therapy.

A groundbreaking study has revealed that a new lung cancer pill significantly cuts the risk of death by 50%.

New treatments like immunotherapy and targeted therapy are improving post-surgery outcomes for lung cancer, with research ongoing to optimize these methods.

Patients with early-stage EGFR-mutated non-small cell lung cancer benefited from treatment with osimertinib, results of the phase 3 ADAURA trial showed.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.

Mirati’s new lung cancer drug Krazati, targeting KRAS mutations, secures FDA approval, offering hope for advanced NSCLC patients.